Archer 1009:a Randomized, Double Blind Phase 3 Efficacy And Safety Study Of Pf-00299804 (Dacomitinib) Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy
Archer 1009:a Randomized, Double Blind Phase 3 Efficacy And Safety Study Of Pf-00299804 (Dacomitinib) Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy
This is a multinational, multicenter, randomized,double-blinded, Phase 3 study comparing the efficacy and safety of treatment with PF-00299804 to treatment with erlotinib in patients with advanced non-small cell lung cancer, previously treated with at least one prior regimen. Analyses of primary objective (Progression Free Survival) will be done in two co-primary populations as defined in the protocol.
Inclusion Criteria:
Exclusion Criteria:
Chandler, Arizona 85224, United States
Chandler, Arizona 85224, United States
Gilbert, Arizona 85297, United States
Mesa, Arizona 85202, United States
Los Angeles, California 90095, United States
Los Angeles, California 90095, United States
Starkville, Mississippi 39759, United States
Lebanon, New Hampshire 03756, United States
Norman, Oklahoma 73071, United States
Oklahoma City, Oklahoma 73120-8347, United States
Corvallis, Oregon 97330, United States
Vienna, 1140, Austria
Wuhan, Hubei 430023, China
Helsinki, 00290, Finland
Zalaegerszeg-Pozva, 8900, Hungary
Osakasayama-shi, Osaka 589-8511, Japan
Sakai-Shi, Osaka 591-8555, Japan
Sunto-gun, Shizuoka 411-8777, Japan
Chuo-Ku, Tokyo 104-0045, Japan
Ube-shi, Yamaguchi 755-0241, Japan
Fukuoka, 811-1395, Japan
Koto-ku, Tokyo, 135-8550, Japan
Krasnodar, Krasnodarskiy Kray 350012, Russia
Pyatigorsk, Stavropolskij Kraj 357340, Russia
Bratislava, 826 06, Slovakia
Parktown,Johannesburg, Gauteng 2193, South Africa
Barcelona, 08041, Spain
Seville, 41013, Spain
Wolverhampton, West Midlands WV10 0QP, United Kingdom